Losing the needle: Using eye drop-based switchable gene therapy as a non-invasive controlled intervention in neovascular blindness
Grant number: 1185600 | Funding period: 2020 - 2023
Related publications (5)
RNA-targeting strategies as a platform for ocular gene therapy.
Satheesh Kumar, Lewis E Fry, Jiang-Hui Wang, Keith R Martin, Alex W Hewitt, Fred K Chen, Guei-Sheung Liu
Genetic medicine is offering hope as new therapies are emerging for many previously untreatable diseases. The eye is at the forefr..
Topical application of TAK1 inhibitor encapsulated by gelatin particle alleviates corneal neovascularization
Jiang-Hui Wang, Ching-Li Tseng, Fan-Li Lin, Jinying Chen, Erh-Hsuan Hsieh, Suraj Lama, Yu-Fan Chuang, Satheesh Kumar, Linxin Zhu, Myra B McGuinness, Jessika Hernandez, Leilei Tu, Peng-Yuan Wang, Guei-Sheung Liu
Rationale: Corneal neovascularization (CoNV) is a severe complication of various types of corneal diseases, that leads to permanen..
TAK1 signaling is a potential therapeutic target for pathological angiogenesis
Linxin Zhu, Suraj Lama, Leilei Tu, Gregory J Dusting, Jiang-Hui Wang, Guei-Sheung Liu
Angiogenesis plays a critical role in both physiological responses and disease pathogenesis. Excessive angiogenesis can promote ne..
A drug-tunable Flt23k gene therapy for controlled intervention in retinal neovascularization
Jinying Chen, Fan-Li Lin, Jacqueline YK Leung, Leilei Tu, Jiang-Hui Wang, Yu-Fan Chuang, Fan Li, Hsin-Hui Shen, Gregory J Dusting, Vickie HY Wong, Leszek Lisowski, Alex W Hewitt, Bang V Bui, Jingxiang Zhong, Guei-Sheung Liu
Gene therapies that chronically suppress vascular endothelial growth factor (VEGF) represent a new approach for managing retinal v..